文献速递淋巴瘤

弥漫性大B细胞淋巴瘤中国际预后指数的生物学特征

Biological signatures of the International Prognostic Index in diffuse large B-cell lymphoma.
PubMed 文献 · Blood Adv · 2024-01-01

研究分析2592例新诊断弥漫性大B细胞淋巴瘤患者的临床数据,其中1233例接受DNA测序检测致癌突变,487例接受RNA测序分析淋巴瘤微环境改变。基于国际预后指数评分将患者分为4组,5年总生存率分别为41.6%、55.3%、71.7%和89.7%。研究发现MCD样亚型与年龄>60岁、多结外受累、血清乳酸脱氢酶升高及国际预后指数评分2至5相关,而ST2样亚型呈相反趋势。

要点

  • 国际预后指数评分4组患者5年总生存率分别为41.6%、55.3%、71.7%和89.7%。
  • MCD样亚型与年龄>60岁、多结外受累、乳酸脱氢酶升高及国际预后指数评分2至5相关。
  • 将TP53Mut整合入国际预后指数可更好区分生存极差的患者。

核心结论

  • 本研究探索了国际预后指数的生物学特征,为未来利用多组学信息优化基于国际预后指数的治疗策略提供了有用依据。

研究设计与样本

  • 研究分析了2592例新诊断弥漫性大B细胞淋巴瘤患者的临床数据。
  • 其中1233例接受DNA测序检测致癌突变,487例接受RNA测序分析淋巴瘤微环境改变。
  • 根据国际预后指数评分将患者分为4组。

主要发现

  • 4组患者的5年总生存率分别为41.6%、55.3%、71.7%和89.7%。
  • MCD样亚型与年龄>60岁、多结外受累、血清乳酸脱氢酶升高及国际预后指数评分2至5相关,而ST2样亚型呈相反趋势。
  • EZB样MYC+和TP53Mut亚型患者临床结局差且独立于国际预后指数,将TP53Mut整合入国际预后指数可更好区分生存极差的患者。
  • EZB样MYC-、BN2样、N1样和MCD样亚型在国际预后指数评分≥2的患者中预后较差。
  • 生发中心样淋巴瘤微环境在乳酸脱氢酶正常和国际预后指数评分0至1的患者中更常见;间充质样淋巴瘤微环境为独立保护因素,而生发中心样、炎症性和耗竭性淋巴瘤微环境类别与国际预后指数评分2至5的较差预后相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Diffuse large B-cell lymphoma (DLBCL) is a highly aggressive subtype of lymphoma with clinical and biological heterogeneity. The International Prognostic Index (IPI) shows great prognostic capability in the era of rituximab, but the biological signatures of IPI remain to be discovered. In this study, we analyzed the clinical data in a large cohort of 2592 patients with newly diagnosed DLBCL. Among them, 1233 underwent DNA sequencing for oncogenic mutations, and 487 patients underwent RNA sequencing for lymphoma microenvironment (LME) alterations. Based on IPI scores, patients were categorized into 4 distinct groups, with 5-year overall survival of 41.6%, 55.3%, 71.7%, and 89.7%, respectively. MCD-like subtype was associated with age of >60 years, multiple extranodal involvement, elevated serum lactate dehydrogenase (LDH), and IPI scores ranging from 2 to 5, whereas ST2-like subtype showed an opposite trend. Patients with EZB-like MYC+ and TP53Mut subtypes exhibited poor clinical outcome independent of the IPI; integrating TP53Mut into IPI could better distinguish patients with dismal survival. The EZB-like MYC-, BN2-like, N1-like, and MCD-like subtypes had inferior prognosis in patients with IPI scores of ≥2, indicating necessity for enhanced treatment. Regarding LME categories, the germinal center-like LME was more prevalent in patients with normal LDH and IPI scores of 0 to 1. The mesenchymal LME served as an independent protective factor, whereas the germinal center-like, inflammatory, and depleted LME categories correlated with inferior prognosis for IPI scores of 2 to 5. In summary, our work explored the biological signatures of IPI, thus providing useful rationale for future optimization of the IPI-based treatment strategies with multi-omics information in DLBCL.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Wang Y, Shi Q, Shi ZY, et al. Biological signatures of the International Prognostic Index in diffuse large B-cell lymphoma. Blood Adv. 2024. PMID: 38170757. doi:10.1182/bloodadvances.2023011425

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。